Photo Credit: Freepick
The Following is a Summary of “Progression Independent of Relative Activity and Relate-Associated Worseing In Seronegative NMOSD: An International Cohort Study,” Published in the April 2025 Issue of Journal of Neurology by Sirirathnam et al.
PREVIOUS STUDIES SHOW THAT PROGRESSION INDEPENDENT OF RELAPSE ACTIVITY (PIRA) IS RARE IN AQUAPORIN- 4 Antibody-Positive (AQP4-IGG) NEUROMYELITIS OPTICTRUM DISORDER (NMOSD). However, The Disability Accumulation Patterns in Seronegative NMOSD Remain Unchlear.
Researchers Drive the Retrospective Study to Evaluate the Prevalence of Pira and Relate-Associated Worsning (RAW) In Serongative NMOSD.
They Drive the Retrospective, Multicenter Cohort Study of Seronegative Patients with NMOSD from the Msbase Registry. Inclusion Criteria Required at Least 3 Recorded Expanded Disability Status Scale (EDSS) Scores: Baseline, Progression, and 6 Months Confirmed Disability Progression (CDP). For Those with 6-MONTH CDP, Relapse Presence or Absence Between Baseline and Progression Determination Classification As Raw or Pira, respective. Descriptive Statistics were used to present the date.
The results showed 93 patients with a median follow-up of 5.0 years (q1 2.8, q3 8.4). The cohort was 77.4% female, with a median age of the onnsest of 33.9 years (q1 26.1, q3 41.2). Pira was observed in 1 case (1.1%), and raw in 7 cases (7.5%).
Investigators confirmed that cdp is uncommon in seronegative numosd. Given That More Than 3 Quarters of CDP Occur Due to Raw, Therapeutic Strategies Focused Primary on Preventing Relatpses.
